Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review
Standard
Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review. / Heidegger, Isabel; Kesch, Claudia; Kretschmer, Alexander; Tsaur, Igor; Ceci, Francesco; Valerio, Massimo; Tilki, Derya; Marra, Giancarlo; Preisser, Felix; Fankhauser, Christian D; Zattoni, Fabio; Chiu, Peter; Puche-Sanz, Ignacio; Olivier, Jonathan; van den Bergh, Roderik C N; Kasivisvanathan, Veeru; Pircher, Andreas; Virgolini, Irene; Gandaglia, Giorgio; EAU-YAU Prostate Cancer Working Group.
In: THER ADV MED ONCOL, Vol. 14, 17588359221081922, 2022.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review
AU - Heidegger, Isabel
AU - Kesch, Claudia
AU - Kretschmer, Alexander
AU - Tsaur, Igor
AU - Ceci, Francesco
AU - Valerio, Massimo
AU - Tilki, Derya
AU - Marra, Giancarlo
AU - Preisser, Felix
AU - Fankhauser, Christian D
AU - Zattoni, Fabio
AU - Chiu, Peter
AU - Puche-Sanz, Ignacio
AU - Olivier, Jonathan
AU - van den Bergh, Roderik C N
AU - Kasivisvanathan, Veeru
AU - Pircher, Andreas
AU - Virgolini, Irene
AU - Gandaglia, Giorgio
AU - EAU-YAU Prostate Cancer Working Group
N1 - © The Author(s), 2022.
PY - 2022
Y1 - 2022
N2 - Radioligand therapy with Lutetium-177 (177Lu)-Prostate-specific membrane antigen (PSMA) has shown to prolong survival in metastatic castration resistant prostate cancer (mCRPC). One of the major challenges for clinicians in the future is to select those patients who would benefit most from this therapy to position it in the treatment landscape of mCRPC. This, in turn, will lead to the delivery of personalized therapies. In this narrative review article we summarize recent studies investigating both predictive and prognostic clinical, imaging-based, and molecular biomarkers to predict treatment response to 177Lu-PSMA-617 radioligand therapy with the aim of identifying men who should be considered for this approach. Of note, the evidence on the role of biomarkers currently relies on small retrospective trials and their validation in larger prospective cohorts is necessary before these results can be translated in the clinical practice.
AB - Radioligand therapy with Lutetium-177 (177Lu)-Prostate-specific membrane antigen (PSMA) has shown to prolong survival in metastatic castration resistant prostate cancer (mCRPC). One of the major challenges for clinicians in the future is to select those patients who would benefit most from this therapy to position it in the treatment landscape of mCRPC. This, in turn, will lead to the delivery of personalized therapies. In this narrative review article we summarize recent studies investigating both predictive and prognostic clinical, imaging-based, and molecular biomarkers to predict treatment response to 177Lu-PSMA-617 radioligand therapy with the aim of identifying men who should be considered for this approach. Of note, the evidence on the role of biomarkers currently relies on small retrospective trials and their validation in larger prospective cohorts is necessary before these results can be translated in the clinical practice.
U2 - 10.1177/17588359221081922
DO - 10.1177/17588359221081922
M3 - SCORING: Review article
C2 - 35273651
VL - 14
JO - THER ADV MED ONCOL
JF - THER ADV MED ONCOL
SN - 1758-8340
M1 - 17588359221081922
ER -
